NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics (Nasdaq: AVAN) announced today that on August 15, 2007 it received a letter from The NASDAQ Stock Market stating that for the last 10 consecutive business days, the market value for AVANT’s common stock has been below the $50,000,000 minimum requirement for continued inclusion under NASDAQ Marketplace Rule 4450(b)(1)(A) and that AVANT’s total assets and revenue were below the $50,000,000 requirement under Rule 4450(b)(1)(B).
